← Leaderboards
William T Beck
University Of Illinois At Chicago
$4,669,124
Attributed
$4,669,124
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $580.5K · FY2006–12$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,669,124 · 4
By mechanism
R01$4,669,124 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Angela L Tyner$9,149,817
- Tom G Driver$2,862,708
- John L. Nitiss$5,416,388
- Venkata M Reddy$4,643,906
- Vadim V Gaponenko$3,041,834
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMolecularCell PhysiologySignal PathwayRna SplicingApoptosisTumorTumor Suppressor GenesPlayMutationVariantNeoplastic CellMultidrug ResistanceAntineoplasticsMicroarray TechnologyDna TopoisomerasesEnzyme ActivityChromatinCell LineGenetic Promoter ElementDna MethylationBaseAtp-Binding Cassette TransportersMouse Model
Grant awards (17)
Splicing factors as therapeutic targets for the treatment of ovarian cancer$307,810
R01 · FY2012 · CA · contact PI
Splicing factors as therapeutic targets for the treatment of ovarian cancer$303,952
R01 · FY2011 · CA · contact PI
Splicing factors as therapeutic targets for the treatment of ovarian cancer$313,715
R01 · FY2010 · CA · contact PI
Characteristics of Multidrug Resistance in Human Tumors$261,339
R01 · FY2010 · CA · contact PI
Functions of MRP2 and MRP3 in Drug Disposition$5,400
R01 · FY2010 · CA · contact PI
Splicing factors as therapeutic targets for the treatment of ovarian cancer$314,066
R01 · FY2009 · CA · contact PI
Characteristics of Multidrug Resistance in Human Tumors$261,339
R01 · FY2009 · CA · contact PI
Characteristics of Multidrug Resistance in Human Tumors$261,339
R01 · FY2008 · CA · contact PI
Characteristics of Multidrug Resistance in Human Tumors$264,099
R01 · FY2007 · CA · contact PI
Characteristics of Multidrug Resistance in Human Tumors$280,053
R01 · FY2006 · CA · contact PI
MICRODETECTION ASSAY FOR DRUG RESISTANT TUMORS$329,275
R01 · FY2003 · CA
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS$279,540
R01 · FY2003 · CA
MICRODETECTION ASSAY FOR DRUG RESISTANT TUMORS$329,275
R01 · FY2002 · CA
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS$279,540
R01 · FY2002 · CA
MICRODETECTION ASSAY FOR DRUG RESISTANT TUMORS$319,302
R01 · FY2001 · CA
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS$279,540
R01 · FY2001 · CA
CHARACTERISTICS OF MULTIDRUG RESISTANCE IN HUMAN TUMORS$279,540
R01 · FY2000 · CA